Fig. 1
From: Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Resistance mechanisms reported for osimertinib according to the line of treatment. The two pie charts depict resistance mechanisms that have been identified in tissue and/or in plasma after resistance to second-line and first-line osimertinib, respectively. Only studies that enrolled more than 15 patients have been taken into account for the ranges of the percentages. In some cases, different molecular aberrations might co-exist in the same patient
